Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26112782 | 0.97 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL3168997 | 0.97 | — | — | |
| SCHEMBL26112778 | 0.97 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL14862483 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL10086229 | 0.87 | SMN1; SMN2 (0.45) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL18116864 | 0.87 | SMN1; SMN2 (0.45) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL9425142 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1 | |
| SCHEMBL1827648 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1 | |
| SCHEMBL22502735 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB | |
| SCHEMBL21916545 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2L3MBTL3L3MBTL1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101367794-B | Preparation method for quinazoline derivants and medical uses thereof | SHANGHAI HENGRUI PHARM CO LTD | 2013-07-10 | — | — | CN | disclosed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| CN-101367794-A | Preparation method for quinazoline derivants and medical uses thereof | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2009-02-18 | — | — | CN | disclosed |
| CN-1304374-C | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same | YUNGJIN PHARMACEUTICAL CO LTD (KR) | 2007-03-14 | — | — | CN | disclosed |
| CN-1662505-A | Quinoline derivatives useful as caspase-3 inhibitors, process for their preparation and pharmaceutical compositions containing them | YUNGJIN PHARMACEUTICAL CO LTD (KR) | 2005-08-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | HIF1AN, HIF1A, VHL | SMN1; SMN2 3418/4885L3MBTL3 4516/4885L3MBTL1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.